ISSN: 2578-3335 (Print) 2578-3343 (Online)
Volume 2

Issue 1

Article 6

2020

Multidisciplinary Approach to Diagnosing and Managing a Case of
Peritoneal Mesothelioma
Jonathan Maw D.O.
Los Angeles County+USC Medical Center, j.maw24@gmail.com

Geoffrey Kelly M.D. Candidate
Cooper Medical School of Rowan University, kellyg61@rowan.edu

Miriam Enriquez M.D.
Cooper University Hospital, eniriquez-miriam@cooperhealth.edu

Ronak Gor D.O.
Cooper University Hospital, gor-ronak@cooperhealth.edu

Pauline Germaine D.O.
Cooper University Hospital, germaine-pauline@CooperHealth.edu

Cooper Rowan Medical Journal: https://rdw.rowan.edu/crjcsm
Would you like to be a reviewer? Please fill in this short form to express your interest.
Recommended Citation
Maw, Jonathan D.O.; Kelly, Geoffrey M.D. Candidate; Enriquez, Miriam M.D.; Gor, Ronak D.O.; and Germaine,
Pauline D.O. (2020) "Multidisciplinary Approach to Diagnosing and Managing a Case of Peritoneal
Mesothelioma," Cooper Rowan Medical Journal: Vol. 2 : Iss. 1 , Article 6.
DOI: 10.31986/issn.2578-3343_vol2iss1.6
Available at: https://rdw.rowan.edu/crjcsm/vol2/iss1/6

This work is licensed under a Creative Commons Attribution 4.0 License.
This Case Reports and Case Series is brought to you for free and open access by the Rowan University Journals at
Rowan Digital Works. It has been accepted for inclusion in Cooper Rowan Medical Journal by an authorized editor
of Rowan Digital Works. For more information, please contact brush@rowan.edu.

Multidisciplinary Approach to Diagnosing and Managing a Case of Peritoneal
Mesothelioma

This case reports and case series is available in Cooper Rowan Medical Journal: https://rdw.rowan.edu/crjcsm/vol2/
iss1/6

Maw et al.: Multidisciplinary Approach to a Case of Peritoneal Mesothelioma

Multidisciplinary Approach to Diagnosing and Managing
a Case of Peritoneal Mesothelioma
Jonathan Maw, D.O.1∗, Geoffrey Kelly, M.D. Candidate2, Miriam Enriquez, M.D.3,
Ronak Gor, D.O.4 & Pauline Germaine, D.O.5
1

Radiology Residency, Los Angeles County+USC Medical Center, Los Angeles, California, United States
2
3
4

Cooper Medical of Rowan University, Camden, NJ, United States

Pathology, Cooper University Hospital, Camden, NJ, United States

Surgery and Urology, Cooper University Hospital, Camden, NJ, United States
5

Radiology, Cooper University Hospital, Camden, NJ, United States

*Corresponding author: j.maw24@gmail.com (Jonathan Maw, D.O.)

ABSTRACT
Peritoneal mesothelioma is a rare cause of a peritoneal mass in adults and can occur in malignant or
benign forms. Compared to the pleural variant of mesothelioma, the peritoneal form is understudied due to
the small number of reported cases. We present a case of an 84-year-old male with a history of asbestos
exposure who initially presented for an aggravated hernia, was found to have an incidental mass on
1

imaging, and ultimately was diagnosed with malignant peritoneal mesothelioma (MPM) likely related to
prior asbestos exposure. This case study will provide a review of literature and discuss the role of imaging
for MPM.
Keywords: malignant peritoneal mesothelioma, asbestosis, pleural mesothelioma, imaging in peritoneal
mesothelioma, MPMCT index, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy

INTRODUCTION

Malignant peritoneal mesothelioma is an extremely rare form of malignant mesothelioma. Malignant
mesotheliomas are neoplasms that arise from mesothelial cells or the serosal mesenchymal cells of the
pleura, peritoneum, pericardium, or tunica vaginalis of the testis; the pleural variant is the most common1.
Out of approximately 3300 cases of mesothelioma diagnosed in the US every year, about 10-15 percent are
of peritoneal origin2,3. Studies have shown that of the ~3000 reported diagnosed pleural mesothelioma
cases per year in the US from 2003 to 2008, there is a significant predominance of men diagnosed. In
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contrast, of the 300-400 newly diagnosed cases of MPM per year, the prevalence between men and women
is approximately equal3. With the exception of asbestos exposure as a predominant risk factor, there is
unclear evidence whether the molecular pathogenesis of peritoneal carcinoma is similar to that of pleural
mesothelioma. Studies showing different gene expression profiles of pleural and malignant mesotheliomas
suggest differences4. Since it is an extremely rare disease, there is no data available from randomized
controlled studies regarding the imaging findings and treatment options for MPM. Thus, there is
significant value in studying individual cases involving such a rare disease with limited data available.
Case report
An 84-year-old male with a medical history of colon cancer, COPD, and a ventral midline hernia initially
presented to the emergency department (ED) after he aggravated the hernia by pulling a plant out of his
yard. Upon presentation, the patient’s symptoms were unimpressive except for pain from the hernia.
Physical examination was positive for an approximately 3 cm midline epigastric hernia with no abdominal
distension. Abdomen was only tender to palpation in the area of the hernia. Initial computed tomography
(CT) abdomen and pelvis was notable for an incidental 8.2 x 3.9 x 3.3 cm pelvic mass abutting the bladder
and sigmoid colon (Figures 1 and 2), mild ascites, a mildly thickened overlying peritoneum, and a small
region of nodular peritoneal thickening. Subsequent colonoscopy was done to rule out a gastrointestinal
primary as the source of the mass and showed no extrinsic compression/evidence of disease recurrence of
colon cancer. Three months following the colonoscopy, MRI pelvis without and with contrast showed
further enlargement of the complex, solid and cystic mass in the pelvis displacing nearby structures
(Figures 3 and 4). Tissue sampling was performed via ultrasound-guided biopsy utilizing a 20-gauge
needle. In addition, ~ 100 cc of gelatinous material was aspirated. Cytology results of the gelatinous
material showed clusters of proliferative mesothelial cells. However, the specimen results from core needle
biopsy were inconclusive. Subsequently, the patient transferred his care to a tertiary center where review
of previously obtained imaging was performed, highlighting presence of calcified and noncalcified pleural
plaques at the lung bases. Review of social history during the multidisciplinary tumor board discussion
confirmed prior asbestos exposure. This occupational exposure history, along with the colonoscopy
showing no evidence of primary colon cancer, raised the concern for malignant mesothelioma as a possible
etiology of the pelvic mass. It was decided surgical management was the best approach to obtain definite
tissue diagnosis and alleviate regional mass effect. Preoperative CT urogram revealed further enlargement
of the pelvic mass, with lateral deviation and decreased caliber of both ureters as well as compression and
anterior displacement of the bladder by the mass (Figure 5).
Two weeks after tumor board, the patient was ultimately taken to the operating room and underwent
radical en bloc resection of pelvic mass >10 cm (Figure 6) with complete colectomy and end-loop
https://rdw.rowan.edu/crjcsm/vol2/iss1/6
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ileostomy performed by a surgical oncologist as well as ureterolysis by a urologist. Surgical pathology
revealed a tumor consisting of infiltrating epithelioid cells, arranged in nests, tubules, and papillary-like
structures (Figure 7). Immunohistochemistry revealed positive staining for mesothelial markers including
calretinin, cytokeratin 5/6, and D240 (Figure 8); immunostains for adenocarcinoma (BerEP4, Tag72) and
specifically, colorectal carcinoma markers (CK20, CDX2, SATB2) were negative. The final diagnosis was
epithelioid malignant mesothelioma involving the peritoneum, serosal aspect of the colon, and the small
bowel.
Patient was then discharged to a long-term acute care hospital (LTACH) with follow-up scheduled with
surgical oncology and urology. However, the patient expired about a month after surgery secondary to
cardiac arrest at long term acute care hospital.

DISCUSSION

Clinical Presentation
MPM presents with vague, nonspecific symptoms and imaging findings. Presentation varies from
incidental imaging findings with no clinical symptoms to abdominal pain, distension, early satiety,
dysphagia, shortness of breath, and weight loss. Abdominal distension is the most common initial
symptom; abdominal pain is the second most common5. Our patient’s only symptom at presentation was
abdominal pain, which was focal and attributed to the hernia.
Risk factors
Several risk factors for the development of MPM have been studied. Similar to other types of
mesotheliomas, there is an association between asbestos exposure and development of MPM6. However,
the link between asbestos exposure is not as strong in the development of MPM as compared to pleural
mesothelioma, particularly in women7 and requires more cumulative asbestos exposure8. Studies have
also shown an increased risk of developing MPM in patients who received direct peritoneal radiation9. In
addition, there are some genetic links to MPM. Pleural malignant mesothelioma has been linked to the loss
of BAP1, NF2, and CDKN2A tumor suppressor genes. A study showed that loss of BAP1 alone without
the loss of NF2 and CDKN2A was linked to MPM, suggesting that pleural and peritoneal mesotheliomas
have distinct genomic features10.
Pathological Features
MPM can be classified on a macroscopic level as either diffuse or focal. Gross pathology of diffuse MPM
appears as multiple grey or white nodules scattered around the peritoneum. Advanced diffuse MPM can
spread and encase the peritoneal cavity and intraperitoneal organs, causing the small bowel to become
fixed, rigid, and immobile. Focal MPM usually forms a solid mass (Figure 6) but can also form masses
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with cystic and mucoid regions. Diffuse MPM may extend into the retroperitoneum, abdominal wall, or
diaphragm and into the pleural cavity1. Out of all malignant mesotheliomas, approximately 85% are
diffuse. Resectable, localized cases are rare11.
Diagnosis of MPM is made by biopsy. Cytologic analysis of ascitic fluid can be used for diagnosis, but is
often inconclusive and has a low yield due to the low number of malignant cells in ascites and the
significant cytologic diversity of tumor cells12,13. It also does not allow for assessment of true stromal
invasion into the peritoneum or viscera, limiting assessment of true malignant extent with invasion. Biopsy
of solid tumor in comparison, allows the ability to assess stromal invasion12.
Histologically MPM can be divided into three subtypes. Epithelioid subtype carries the best prognosis,
while the sarcomatous and mixed subtypes carry a poorer prognosis. The epithelioid subtypes appear most
like normal mesothelial cells in a tubulopapillary or trabecular pattern. The sarcomatoid subtype consists
of tightly packed spindle cells with occasional presence of malignant osteoid, chondroid, or muscular
elements. The biphasic subtype consists of both components with each contributing at least 10% of the
overall histology1. Approximately 75% of MPM are of the epithelioid subtype, while the biphasic subtype
is ~ 25%. The sarcomatoid subtype is extremely rare and is almost 0% of MPM13. Our patient’s
core-needle biopsy was inconclusive; fluid cytology suggested the diagnosis and the surgical resection
ultimately resulted in histologic sections most consistent with the epithelioid subtype (Figure 7).
There are no markers that are specific for malignant mesothelioma in immunohistological analysis.
However, markers such as calretinin, D240, WT1, and cytokeratin 5/6 are used to help differentiate
malignant mesotheliomas from other carcinomas with similar histologic appearance1. Figure 8 shows
tumor cells with reactivity with calretinin, supporting mesothelial differentiation of the mass in our case.
Imaging Features
CT scan is the most common initial imaging modality used in diagnosing MPM as it is usually the initial
test ordered in a patient presenting with abdominal pain or increased abdominal girth. There is a wide
spectrum of imaging findings in MPM, but results most commonly include a thickening of the mesentery
and peritoneum14. It can be classified by distinct patterns on cross-sectional imaging that reflect its gross
pathologic appearance: diffuse peritoneal cavity involvement or focal intraperitoneal mass. While imaging
findings for MPM are variable, diffuse MPM is most commonly characterized as widespread diffuse
involvement of the peritoneum with tumor infiltrating and thickening the peritoneum, in a sheet-like
fashion, leading to an irregular and nodular pattern. Focal MPM can present as dominant intraperitoneal
mass associated with peritoneal studding, sometimes with omental caking. Omental caking can appear as
fine, nodular, soft-tissue studding or coalescent, mass-like soft tissue in the omentum. In addition,
sometimes calcifications related to the malignant osteoid, chondroid, or muscular elements of the
https://rdw.rowan.edu/crjcsm/vol2/iss1/6
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sarcomatoid subtype can be seen on CT scan1.
Since CT findings for MPM are highly variable, differentiating MPM from other peritoneal masses such as
carcinomatosis, gastrointestinal malignancies, ovarian carcinomas, and lymphomas is difficult. A study
that compared the CT findings of MPM with non-MPM peritoneal masses showed three statistically
significant characteristics for differentiating MPM from non-MPM masses: multiple nodular lesions, mild
to massive thickening of the mesentery, and presence of pleural plaques. While not statistically significant,
it also showed the MPM group had a higher proportion of cases with moderate to massive accumulation of
ascites, nodular lesions with a maximum dimension of <1 cm, and irregular or massive thickening of the
peritoneum14. However, since there is no single imaging finding that is specific to MPM13, suspicion of
MPM is made from imaging findings in addition to clinical context; final diagnosis is made from biopsy.
Studies demonstrate that fat-suppressed and delayed gadolinium-enhanced magnetic resonance imaging
(MRI) can be of use to accurately estimate the burden of peritoneal disease because the contrast
enhancement allows depiction of sub-centimeter deposits and deposits located in anatomically difficult
sites to see on CT, such as the subphrenic, mesenteric areas, and along the bowel serosal surfaces15.
However, this is not well defined for MPM13. MRI is used less commonly than CT for MPM and shows a
mass with low-intermediate signal on T1 weighted images, and high signal on T2 weighted images
Figure 4 due to internal necrosis16. It is most commonly used as a primary imaging modality for MPM for
patients who cannot tolerate IV contrast. Similarly, while positive emission tomography (PET) and
PET/CT scans are often used to stage cancers, it is unclear if they have any value in staging MPM13. Due
to small size of peritoneal deposits, they may be associated with low level activity on PET and PET/CT,
making assessment of true extent of disease involvement difficult. Localized mass is frequently associated
with significant degree of necrosis, further limiting the applicability of PET.
CT images of our patient had all three of the distinguishing findings of MPM including nodular lesions,
thickening of the peritoneum, and presence of pleural plaques. MRI confirmed the progressive
enlargement of the mass over time; no additional information was revealed by MRI in comparison to the
initial CT. Careful review of imaging studies raised the possibility of MPM and guided surgical planning.
Treatment
Most research on MPM treatment has been in the form of retrospective single-center series, which is prone
to inherent selection biases. Data on systemic chemotherapy is mainly available through Expanded Access
Programs (outside of clinical trials). Historically MPM was treated with systemic chemotherapy but with
modest survival rates with a median survival rate between 10-26.8 months17. Recent advancements have
led to treatment with a combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal
chemotherapy (HIPEC), which has shown improved outcomes over surgery or chemotherapy alone17.
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Imaging plays a role in management of MPM and can guide surgical planning. Localized MPM has a
better prognosis and responds better to surgical resection14. The goal of cytoreductive surgery is to remove
as much tumor as possible. Chemotherapy can be done systemically or directly into the abdomen
(intraperitoneal chemotherapy) after surgery or through an abdominal catheter. Intraperitoneal therapy is
considered more effective over systemic therapy because of enhanced concentrations in the area of tumor
and decreased systemic toxicity. Studies show the overall response rate with a single agent chemotherapy,
combined chemotherapy, intraperitoneal chemotherapy, and continuous hyperthermic peritoneal perfusion
are 13.1%, 20.5%, 47.4%, and 84.6% respectively18. Cisplatin is the most studied chemotherapy agent,
and is often used with mitomycin C, fluorouracil, doxorubicin, and/or paclitaxel for intraperitoneal
chemotherapy. Cisplatin and pemetrexed are often used in combination for systemic chemotherapy in both
pleural and peritoneal mesothelioma. Systemic chemotherapy is more often used in cases where the tumor
is unresectable3. For our patient, since the final diagnosis was not available and the patient was
experiencing lower urinary symptoms, debulking surgery with biopsy was done to provide a diagnosis and
alleviate his symptoms. Hence, HIPEC or chemotherapy was not originally considered. Unfortunately, the
patient passed away before further treatment could be offered.

CONCLUSION

In conclusion, MPM is a rare disease that is difficult to diagnose based on its vague symptoms and
nonspecific imaging findings. A history of asbestos exposure or pleural plaques should raise the index of
suspicion for MPM in evaluation of an abdominal or pelvic mass because early diagnosis and treatment
can lead to better outcomes. A multimodality approach is appropriate in the diagnosis and management of
MPM. Imaging can lead to suspicion of MPM, show progression of disease, and help guide surgical
planning for debulking. Final diagnosis is made by biopsy. The most effective treatment outcomes have
resulted from a combination of surgical resection and chemotherapy.

https://rdw.rowan.edu/crjcsm/vol2/iss1/6
DOI: 10.31986/issn.2578-3343_vol2iss1.6

73

Maw et al.: Multidisciplinary Approach to a Case of Peritoneal Mesothelioma

Figure 1 Figures one and two description: Axial and coronal images from the initial CT of the abdomen and pelvis
show an incidental heterogeneously enhancing solid and cystic pelvic mass (thick blue arrows)abutting the bladder
(yellow triangle) and the rectum (thin red arrow).
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Figure 2 Figures one and two description: Axial and coronal images from the initial CT of the abdomen and pelvis
show an incidental heterogeneously enhancing solid and cystic pelvic mass (thick blue arrows)abutting the bladder
(yellow triangle) and the rectum (thin red arrow).
https://rdw.rowan.edu/crjcsm/vol2/iss1/6
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Figure 3 Figures three and four description: Coronal and axial images obtained with echo-planar fast spin echo
sequences show further enlargement of complex, solid and cystic mass in the pelvis (blue arrows) displacing nearby
structures, including the bladder(yellow triangles).
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Figure 4 Figures three and four description: Coronal and axial images obtained with echo-planar fast spin echo
sequences show further enlargement of complex, solid and cystic mass in the pelvis (blue arrows) displacing nearby
structures, including the bladder(yellow triangles).
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Figure 5 Axial image from preoperative CT urogramshows further enlargement of the pelvic mass (thick blue
arrow), with lateral deviation and decreased caliber of both ureters (thin blue arrows) as well as compression and
anterior displacement of the bladder by the mass (yellow triangle).
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Figure 6 Gross specimen of the pelvic mass from radical en block resection,showing a dominant 22 cm mass
involving the colonic wall, with multiple tumorimplants along the serosal surface and in the mesenteric fat.
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Figure 7 The tumor consists of epithelioid cells arranged variably in nests, tubules, and many papillary-like
structures, which are depicted here (black arrow). (H&E 100x).

Published by Rowan Digital Works, 2020

80

Cooper Rowan Medical Journal, Vol. 2, Iss. 1 [2020], Art. 6

Figure 8 The tumor cells showedstrong immunoreactivity with calretinin (black arrow), supporting mesothelial
differentiation (immunostain 100x).
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